Consun Pharmaceutical Group Limited (HKG:1681)
Hong Kong
· Delayed Price · Currency is HKD 15.99
-0.12 (-0.74%)
Apr 29, 2026, 4:08 PM HKT
HKG:1681 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,417 | 2,967 | 2,590 | 2,340 | 2,045 | Upgrade
|
| Revenue Growth (YoY) | 15.17% | 14.56% | 10.71% | 14.43% | 16.65% | Upgrade
|
| Cost of Revenue | 750.24 | 725.13 | 668.44 | 576.74 | 517.32 | Upgrade
|
| Gross Profit | 2,667 | 2,242 | 1,922 | 1,763 | 1,527 | Upgrade
|
| Selling, General & Admin | 1,518 | 1,293 | 1,168 | 1,094 | 900 | Upgrade
|
| Other Operating Expenses | -2.32 | -17.55 | -59.45 | -14.47 | -14.8 | Upgrade
|
| Operating Expenses | 1,515 | 1,267 | 1,096 | 1,048 | 867.15 | Upgrade
|
| Operating Income | 1,152 | 974.99 | 825.92 | 715.41 | 660.18 | Upgrade
|
| Interest Expense | -4.36 | -24.89 | -21.26 | -10.93 | -12.91 | Upgrade
|
| Interest & Investment Income | 85.28 | 88.3 | 68.92 | 52.41 | 39.25 | Upgrade
|
| Earnings From Equity Investments | -1.6 | -0.07 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -33.03 | -17.88 | -9.03 | -9.28 | 11.33 | Upgrade
|
| EBT Excluding Unusual Items | 1,198 | 1,020 | 864.55 | 747.61 | 697.85 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.93 | -0.35 | -0.85 | -1.22 | -1.99 | Upgrade
|
| Pretax Income | 1,196 | 1,020 | 863.7 | 746.39 | 695.86 | Upgrade
|
| Income Tax Expense | 107.29 | 102.73 | 77.15 | 62.7 | 108.74 | Upgrade
|
| Earnings From Continuing Operations | 1,089 | 917.37 | 786.55 | 683.7 | 587.12 | Upgrade
|
| Minority Interest in Earnings | -11.07 | -6.92 | -2.02 | -0.79 | 3.06 | Upgrade
|
| Net Income | 1,078 | 910.46 | 784.53 | 682.91 | 590.17 | Upgrade
|
| Net Income to Common | 1,078 | 910.46 | 784.53 | 682.91 | 590.17 | Upgrade
|
| Net Income Growth | 18.41% | 16.05% | 14.88% | 15.71% | 18.32% | Upgrade
|
| Shares Outstanding (Basic) | 848 | 821 | 791 | 791 | 802 | Upgrade
|
| Shares Outstanding (Diluted) | 855 | 832 | 799 | 792 | 805 | Upgrade
|
| Shares Change (YoY) | 2.77% | 4.12% | 0.91% | -1.58% | -1.54% | Upgrade
|
| EPS (Basic) | 1.27 | 1.11 | 0.99 | 0.86 | 0.74 | Upgrade
|
| EPS (Diluted) | 1.26 | 1.09 | 0.98 | 0.86 | 0.73 | Upgrade
|
| EPS Growth | 15.60% | 11.22% | 13.95% | 17.81% | 19.67% | Upgrade
|
| Free Cash Flow | - | 977.99 | 766.41 | 896.09 | 627.29 | Upgrade
|
| Free Cash Flow Per Share | - | 1.18 | 0.96 | 1.13 | 0.78 | Upgrade
|
| Dividend Per Share | 0.656 | 0.564 | 0.408 | 0.265 | 0.244 | Upgrade
|
| Dividend Growth | 16.35% | 38.03% | 53.92% | 8.58% | 3.66% | Upgrade
|
| Gross Margin | 78.05% | 75.56% | 74.19% | 75.35% | 74.70% | Upgrade
|
| Operating Margin | 33.71% | 32.86% | 31.89% | 30.58% | 32.29% | Upgrade
|
| Profit Margin | 31.55% | 30.68% | 30.29% | 29.19% | 28.86% | Upgrade
|
| Free Cash Flow Margin | - | 32.96% | 29.59% | 38.30% | 30.68% | Upgrade
|
| EBITDA | 1,209 | 1,032 | 897.51 | 785.89 | 728.71 | Upgrade
|
| EBITDA Margin | 35.37% | 34.77% | 34.65% | 33.59% | 35.64% | Upgrade
|
| D&A For EBITDA | 56.73 | 56.73 | 71.58 | 70.48 | 68.53 | Upgrade
|
| EBIT | 1,152 | 974.99 | 825.92 | 715.41 | 660.18 | Upgrade
|
| EBIT Margin | 33.71% | 32.86% | 31.89% | 30.58% | 32.29% | Upgrade
|
| Effective Tax Rate | 8.97% | 10.07% | 8.93% | 8.40% | 15.63% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.